Mikhail Rojavin

Mikhail Rojavin is currently the Senior Scientific Director of Clinical Development at Amgen since October 2023, after Horizon was acquired by Amgen. Prior to this, Mikhail held the same position at Horizon since September 2022. With extensive experience in the pharmaceutical industry, Mikhail previously worked as the Global Clinical Program Director at CSL Behring, a CTL at Novartis Pharma, and a Senior Clinical Research Associate at Omnicare Clinical Research. Mikhail also has experience as an Assistant Professor at Temple University School of Medicine and as a Founder and Scientific Director at Autovaccine Research Center. Mikhail holds a PostDoc in Pharmacology from Temple University and a Ph.D. in Microbiology from Ukrainian National Academy of Sciences.